Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. The company offers swine fever live vaccines; trivalent inactivated vaccines for piglets; inactivated vaccine for streptococcus suis; pseudorabies live vaccines; inactivated oil emulsion vaccine of porcine parvovirus disease; pathogenic porcine reproductive and respiratory syndrome live vaccines; transmissible gastroenteritis, porcine epidemic diarrhea, and porcine rotavirus triple live vaccines; porcine reproductive and respiratory syndrome live vaccines; swine transmissible gastroenteritis and swine epidemic diarrhea combined inactivated vaccines; porcine circovirus type 2 inactivated vaccines; and swine Japanese encephalitis live vaccines. It also provides chicken infectious bursal disease live vaccines; inactivated avian infectious rhinitis vaccines; newcastle disease and avian influenza combined inactivated vaccines; newcastle disease, infectious bronchitis, egg drop syndrome, and avian influenza quadruple inactivated vaccines; avian influenza inactivated vaccines; newcastle disease, infectious bronchitis, and avian influenza triple inactivated vaccines; avian infectious bronchitis live vaccines; avian newcastle disease and avian infectious bronchitis combined live vaccines; newcastle disease low virulent live vaccines; Marek's disease turkey herpes virus live vaccines; and fowlpox live vaccines. The company was founded in 1981 and is based in Shanghai, China.
Shanghai Hile Bio-Technology Dividend Announcement
• Shanghai Hile Bio-Technology announced a annually dividend of ¥0.03 per ordinary share which will be made payable on 2024-07-19. Ex dividend date: 2024-07-19
• Shanghai Hile Bio-Technology annual dividend for 2024 was ¥0.03
• Shanghai Hile Bio-Technology annual dividend for 2023 was ¥0.06
• Shanghai Hile Bio-Technology's trailing twelve-month (TTM) dividend yield is 0.33%
• Shanghai Hile Bio-Technology's payout ratio for the trailing twelve months (TTM) is 23.40%
Shanghai Hile Bio-Technology Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-07-19 | ¥0.03 | annually | 2024-07-19 |
2023-07-13 | ¥0.06 | annually | 2023-07-13 |
2021-07-01 | ¥0.00 | annually | 2021-07-01 |
2020-07-15 | ¥0.01 | annually | 2020-07-15 |
2019-07-18 | ¥0.01 | annually | 2019-07-18 |
2018-07-26 | ¥0.06 | annually | 2018-07-26 |
2017-07-07 | ¥0.04 | annually | 2017-07-07 |
2016-05-05 | ¥0.10 | annually |
Shanghai Hile Bio-Technology Dividend per year
Shanghai Hile Bio-Technology Dividend growth
Shanghai Hile Bio-Technology Dividend Yield
Shanghai Hile Bio-Technology current trailing twelve-month (TTM) dividend yield is 0.33%. Interested in purchasing Shanghai Hile Bio-Technology stock? Use our calculator to estimate your expected dividend yield:
Shanghai Hile Bio-Technology Financial Ratios
Shanghai Hile Bio-Technology Dividend FAQ
Other factors to consider when evaluating Shanghai Hile Bio-Technology as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Shanghai Hile Bio-Technology stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Shanghai Hile Bio-Technology's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Shanghai Hile Bio-Technology publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Shanghai Hile Bio-Technology distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Shanghai Hile Bio-Technology are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Shanghai Hile Bio-Technology sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Shanghai Hile Bio-Technology distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Shanghai Hile Bio-Technology declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Shanghai Hile Bio-Technology's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Shanghai Hile Bio-Technology's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.